Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
In this cohort study of 8534 patients with metastatic ccRCC, although ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them; high attrition rates were observed in subsequent lines. These findings highlight the need to optimize treatment selection by implementing current guidelines in clinical practice.
Authors
- Vinay Mathew Thomas (ORCID: https://orcid.org/0000-0001-9916-730X)
- Miguel Zugman (ORCID: https://orcid.org/0000-0002-2181-8405)
- Yeonjung Jo (ORCID: https://orcid.org/0000-0002-1630-2957)
- Benjamin Louis Maughan (ORCID: https://orcid.org/0000-0002-0010-8551)
- Gliceida Galarza Fortuna (ORCID: https://orcid.org/0000-0002-1084-953X)
- Umang Swami (ORCID: https://orcid.org/0000-0003-3518-0411)
- Zeynep İrem Özay (ORCID: https://orcid.org/0000-0002-4827-9042)
- Georges Gebrael (ORCID: https://orcid.org/0000-0002-4085-6415)
- Sumanta Kumar Pal (ORCID: https://orcid.org/0000-0002-1712-0848)
- Nicolas Sayegh (ORCID: https://orcid.org/0000-0003-1924-8148)
- Chadi Hage Chehade (ORCID: https://orcid.org/0009-0008-6735-5777)
- Ethan J. Anderson (ORCID: https://orcid.org/0000-0002-0113-8875)
- Salvador Jaime‐Casas (ORCID: https://orcid.org/0009-0009-4334-1300)
- Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
- Micah Ostrowski (ORCID: https://orcid.org/0009-0004-2096-6352)
Institutions
- City Of Hope National Medical Center (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.1201
- Citations
- 7
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.63